Bio

Publications

All Publications


  • Multi-disciplinary evaluation of a 5-month-old with hypertrophic cardiomyopathy related to a functional adrenocortical tumor. Journal of pediatric endocrinology & metabolism : JPEM Nally, L. M., Conner, E., Paige, S., Mooney, K. L., Naber, U., Richards, R., Wright, G. 2018

    Abstract

    Background Hypertrophic cardiomyopathy (HCM) in childhood is a rare diagnosis, and associations with adrenocortical tumors (ACTs) have been rarely reported in the pediatric literature. Case Presentation We present a case of a 5-month-old who presented with HCM and during the evaluation for hypertension was found to have elevated glucocorticoids, mineralocorticoids, androgens and urine metanephrines. During preoperative evaluation, he developed shock followed by cardiogenic collapse requiring extracorporeal membrane oxygenation (ECMO); however, he did not survive. Pathology revealed an ACT with hormone production that contributed to his demise. Conclusion Adrenocortical tumors associated with hypertrophic cardiomyopathy can be life-threatening. We discuss the complex interplay of unrestricted cortical hormone production in the setting of hypertrophic cardiomyopathy that may lead to rapid decline and poor clinical outcomes.

    View details for PubMedID 30352041

  • CAR T Cell Therapy for Neuroblastoma FRONTIERS IN IMMUNOLOGY Richards, R. M., Sotillo, E., Majzner, R. G. 2018; 9
  • CAR T Cell Therapy for Neuroblastoma. Frontiers in immunology Richards, R. M., Sotillo, E., Majzner, R. G. 2018; 9: 2380

    Abstract

    Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with debilitating long term sequelae from treatment. Even after integration of anti-GD2 monoclonal antibody therapy into standard, upftont protocols, 5-year overall survival rates are only about 50%. The success of anti-GD2 therapy has proven that immunotherapy can be effective in neuroblastoma. Adoptive transfer of chimeric antigen receptor (CAR) T cells has the potential to build on this success. In early phase clinical trials, CAR T cell therapy for neuroblastoma has proven safe and feasible, but significant barriers to efficacy remain. These include lack of T cell persistence and potency, difficulty in target identification, and an immunosuppressive tumor microenvironment. With recent advances in CAR T cell engineering, many of these issues are being addressed in the laboratory. In this review, we summarize the clinical trials that have been completed or are underway for CAR T cell therapy in neuroblastoma, discuss the conclusions and open questions derived from these trials, and consider potential strategies to improve CAR T cell therapy for patients with neuroblastoma.

    View details for PubMedID 30459759

    View details for PubMedCentralID PMC6232778

  • MULTI-DISCIPLINARY EVALUATION OF A 5 MONTH OLD WITH HYPERTROPHIC CARDIOMYOPATHY RELATED TO A FUNCTIONAL ADRENOCORTICAL TUMOR Nally, L. M., Conner, E., Paige, S., Naber, U., Richards, R., Mooney, K. L., Wright, G. KARGER. 2017: 432–33